Cerebrolysin: Evidence, Legal Status, and Safety
Cerebrolysin is a porcine-brain-derived neuropeptide mixture with a genuinely larger human trial base than most peptides discussed online, including Cochrane systematic reviews. For vascular dementia, a Cochrane review of 6 RCTs (597 people) found a small positive effect on cognition, but reviewers did not recommend routine use given small trial numbers and high risk of bias. For acute stroke, a separate Cochrane-aligned analysis found no benefit on survival and a statistically significant increase in non-fatal serious adverse events. It is not FDA-approved in the US.
Understand what's actually being sold
Approval in other countries is real, but it does not establish US approval or safety review.
See what the human evidence actually shows
A Cochrane review finding a small effect is real evidence, but reviewers explicitly stopped short of recommending routine use, and that caveat matters as much as the headline finding.
See the acute-stroke evidence separately
The same compound can show a small benefit in one indication and an adverse-event signal in another; these should never be blended into one blanket claim.
Know where it actually stands
"Approved elsewhere" is a common but misleading argument for US legality; the two are independent regulatory questions.
Know the real risk
An adverse-event signal in one indication is a real safety data point, not a hypothetical concern.
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue, used clinically in dementia and stroke care in roughly 45 countries, but never FDA-reviewed or approved in the US. This page reports the honest evidence tier, legal status, and safety picture; it does not describe how to use it.
Why it worksâ–¼
- Anyone considering Cerebrolysin who wants the honest evidence before discussing it with a clinician
- Readers researching dementia or cognitive-decline peptides who have seen Cochrane-review claims
- Readers comparing Cerebrolysin's evidence quality to the Alzheimer's and cognitive-decline literature more broadly
- Benefit, where found (vascular dementia), is small and reviewers flag high risk of bias and did not recommend routine use
- Stroke-indication data shows an adverse-event signal (increased non-fatal serious adverse events), not a benefit signal
- Not FDA-approved for any indication in the US
- Educational only, not medical advice
Does Cerebrolysin work for dementia?▾
Is Cerebrolysin safe for stroke recovery?▾
Is Cerebrolysin FDA-approved?▾
New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.